跳至主要内容
临床试验/NCT00386763
NCT00386763已完成3 期

A Randomized, Investigator-Blinded, Multicenter, Parallel-Group Study to Compare Efficacy, Safety and Tolerability of Arthemeter/ Lumefantrine Dispersible Tablet Formulation vs. Artemether/ Lumefantrine 6-Dose Crushed Tablet in the Treatment of Acute Uncomplicated Plasmodium Falciparum Malaria in Infants and Children.

Novartis5 个研究点 分布在 5 个国家目标入组 890 人开始时间: 2006年8月1日最近更新:
适应症
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
Novartis
入组人数
890
试验地点
5
主要终点
Proportion of patients free of parasites at day 28.

研究概览

简要总结

This study will evaluate the safety and efficacy of artemether-lumefantrine against uncomplicated malaria caused P. falciparum in children of 5-35 kg bodyweight.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single

入排标准

年龄范围
— 至 12 Years(Child)
性别
All
接受健康志愿者

入选标准

  • male or female infants and children ≤12 years of age
  • body weight of ≥5 kg and <35 kg,
  • with a confirmed diagnosis of uncomplicated malaria caused by the P. falciparum parasite

排除标准

  • complicated malaria
  • persistent vomiting
  • malaria due to parasites other than P. falciparum
  • antimalarial treatment received in the past 2 weeks
  • known chronic disease e.g. positive HIV status, severe cardiac, renal, or hepatic disease

结局指标

主要结局

Proportion of patients free of parasites at day 28.

次要结局

  • Proportion of patients free of parasites at 7 days and at 14 days
  • Time to clearance from parasites
  • Time to clearance of fever
  • Hematology and biochemistry parameters
  • Electrocardiogram

研究者

发起方
Novartis
申办方类型
Industry

研究点 (5)

Loading locations...

相似试验